Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Erin Wright
Period: Reporting periods mapped to calendar 2024 Q3 – 2026 Q3 (9 quarters).
- Questions
- 103on tracked calls
- Challenge rate
- 4%4 of 103 questions
- Companies
- 14questioned at least once
- Reporting periods
- 9with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 103 of 103 questions from 14 companies
IDXXIdexx Laboratories14 questions · 7 reporting periods · 1 of 14 challenging
Calendar 2026 Q2
can you speak a little bit about the rollout of FNA and how that's progressing relative to your expectations
Show response
Mike confirmed inVue Dx consumables are comfortably within the $3,500-$5,500/instrument range and that FNA is on track in its controlled launch, broadening meaningfully into Q3.
can you break down the components of that growth and the sustained market share gains that you're seeing there
Show response
Mike credited Cancer Dx and Fecal Dx for record lab conversions; Andrew acknowledged 1.3% visit declines and deferred long-term growth-algo detail to the upcoming Investor Day.
Calendar 2026 Q1
remind us what actually would be in view related or directly associated with inVue consumables? Is that really moving the needle yet?
Show response
Jay confirmed inVue consumables contributing, representing 100% new growth. Also cited rapid uptake of Catalyst pancreatic lipase and cortisol across large installed base, and international SediVue momentum.
do you have a backlog or preorders to speak of on that front that customers are waiting for F&A
Show response
Jay redirected to broad opportunity (100-150 million manual cytologies globally) rather than directly addressing backlog numbers. Mike added excitement about F&A TAM with 90% of masses currently uninvestigated.
Calendar 2025 Q4
Is that U.S. Market or is it international? Where are you seeing the tangible market share gains
Show response
Jay cited global reference lab gains driven by network investment, enabling infrastructure (LIS, VetConnect PLUS localization), and innovation differentiation (fecal antigen, vector-borne, Cancer Dx). Competitive submissions now approximately 18%, with customers breaking workflow to send Cancer Dx samples as entry point for broader IDEXX adoption.
How should we be thinking about continuing mid-teens growth into 2026 or the cadence that we should be thinking about things here
Show response
Jay attributed consumable growth to combination of 12% installed base expansion, quality placements incentivized by EVI metrics, and Technology for Life menu expansion (SmartQC, PL, Cortisol). InVue tracking well to $3,500-$5,500 per instrument estimate including upcoming FNA. Andrew noted over 1,350 new/competitive Catalyst placements globally in Q4.
Calendar 2025 Q3
how much of the strength is actually InVue consumables, lipase or just the new contracting terms when you do place an InVue
Show response
Jay described consumable growth as broad-based across installed base expansion (10% YoY), specialty tests (PL, SmartQC, Cortisol), and InVue as incremental. Declined to isolate InVue consumable contribution specifically, calling it early stages but proceeding well to plan.
are we still on track with FNA and the launch? And what are you seeing from some of the pilot programs with FNA so far
Show response
Jay confirmed FNA on track for later in 2025. Noted vast majority of InVue customers intend to use all testing modalities including FNA, not just ear cytology or blood morphology. Expects strong cross-adoption.
Calendar 2025 Q2
what's reflected in terms of that office visit trends now? What gets you to the high end, low end of the range?
Show response
Andrew noted visit assumptions updated to ~2.5% decline. Innovation ramp (inVue, Cortisol, Cancer Dx, PL) and lapping of major customer agreements expected to drive momentum.
can you talk a little bit about the contracts that coincide with the placements in terms of consumables agreements
Show response
Jay declined to break out inVue consumable contribution specifically. Noted independent practices move faster on placements while corporates pilot first. Usage in line with expectations.
Calendar 2025 Q1
Could you talk a little bit about Cancer Dx and the pull-through that you're seeing
Show response
Jay noted strong early interest but said it's too early to understand the mix between aid-in-diagnosis vs wellness panel inclusion. Priced to support broad wellness screening inclusion.
what gives you confidence in sort of the pickup and CAG recurring for the balance of the year
Show response
Andrew cited innovation ramps (inVue, Cancer Dx, PL), lapping of large customer agreements providing price and volume tailwinds, and days normalization in H2 as key building blocks.
Calendar 2024 Q4
can you speak to what guidance assumes now in terms of the innovation contribution in 2025?
Show response
Andrew provided specific inVue revenue/placement targets. Jay explained controlled launch approach and confirmed customers are not waiting for FNA to take delivery.
does your guidance assume any sort of notable changes from a customer account standpoint at Point-of-Care or ref lab?
Show response
Andrew confirmed full-year net price realization of 4-4.5% with Q1 at the lower end due to lapping three large customer agreements from 2024.
ZTSZoetis11 questions · 7 reporting periods · 3 of 11 challenging
Calendar 2026 Q2
targeted price actions that you're taking and what's baked into guidance on that front
Show response
Kristin explained the gross-to-net (not list price) focus and expressed confidence in the leadership team, but deferred share-loss quantification to later in the call.
Calendar 2026 Q1
how do you kind of mitigate that? And when could we get back to your typical 6% to 8% operational revenue growth
Show response
Wetteny acknowledged the 200-250bp headwind into 2027 but declined to give 2027 guidance, pointing instead to top and bottom line execution driving P&L leverage.
What does guidance imply now for the quarterly progression for companion animal
Show response
Wetteny was clear that no distributor restock is assumed, inventory levels are at the low end of the post-2023 range, and guidance reflects current end market demand dynamics.
Calendar 2025 Q4
the 3% to 5% operational guidance, does that incorporate what U.S. Companion Animal operational growth is?
Show response
Wetteny declined segment-level guidance. Noted clinic revenue grew ~6% in Q4. International fiscal year alignment shifts are 30-40bps of total company, not material to 3-5% range. OOG definition excludes FX and acquisitions/divestitures >1% of prior-year revenue.
Calendar 2025 Q3
I just wanted to know kind of what meaningfully changed for you kind of on an intra-quarter basis after you raised guidance last quarter?
Show response
Wetteny attributed shortfall to therapeutic visit declines (different from overall visit declines seen in prior years), macro impacts on US clinics, plus anticipated competitive launch dynamics. Emphasized Q4 exit not indicative of 2026 given Librela stabilization, Livestock momentum, and pricing power.
Calendar 2025 Q2
can you speak to some of the areas that you continue to drive from a cost management perspective? And how do you think about the quarterly progression from an operating margin standpoint from here?
Show response
Wetteny attributed margin performance to cost management and manufacturing cost normalization. Cautioned that Q3 faces tough comp (Companion Animal grew 15% last year, US CA 18%). Derm competition launch expected in Q4.
how are you thinking about your ability to still achieve high single-digit, 6% to 8% kind of operational growth next year and some of those just like higher level headwinds and tailwinds as we head...
Show response
Kristin emphasized portfolio diversity, pipeline approvals, and secular growth fundamentals. Wetteny noted it was early to discuss 2026 specifics but pointed to portfolio breadth and strong Livestock momentum continuing.
Calendar 2025 Q1
you speak to what you’re seeing across the US market in terms of the Librela label change, how that’s responding relative to your expectations there?
Show response
Kristin confirmed 17% US Librela growth, strong vet satisfaction, and investments in medical education, post-launch studies, international KOL engagement, and targeted DTC.
can you describe what exactly is embedded in terms of the growth tariff impact and what mitigation efforts you have?
Show response
Wetteny explained exposure primarily from China API imports for livestock and some diagnostics. 60% of manufacturing is US-based, company is net exporter, giving significant mitigation flexibility.
Calendar 2024 Q4
just on the margin improvement year-to-year in 2025, can you talk a little bit about what's driving that in terms of the mix shift with the MFA divestiture
Show response
Wetteny attributed margin improvement to MFA divestiture, favorable companion animal mix, and pricing above historical 2-3%, partially offset by FX (~50bps headwind).
can you speak to how vets are responding following the vet letter and label change? Like, has that helped them in terms of understanding kind of how to prescribe?
Show response
Kristin confirmed label was consistent with international labels, no contraindications/warnings/precautions, and vets found it helpful.
LHLabCorp10 questions · 7 reporting periods · 0 of 10 challenging
Calendar 2026 Q2
Can you just detail a little bit on your overall consumer strategy at this point around DTC testing?
Show response
Adam explained the deliberate choice to build through OnDemand rather than partner into lower-margin consumer channels where pricing erodes.
Calendar 2026 Q1
how would you describe the deal pipeline right now? Like what are you seeing in terms of the pipeline
Show response
Adam confirmed pipeline consistently strong year-over-year. Health systems struggling financially and looking to partner. Noted PAMA implementation could actually increase deal pipeline over time as smaller labs face more pressure.
Calendar 2025 Q4
how do you think about the nature of the deal pipeline now, how it compares to maybe this time last year?
Show response
Adam confirmed robust pipeline driven by hospital financial pressure. Monitoring pipeline size and timing (some state approvals adding time). Long tail of opportunity ahead. Consumer health testing growing strongly but not yet critical mass for separate reporting.
how do you think about the durability of growth across the consumer-driven market?
Show response
Adam detailed three consumer channels: OnDemand (200+ biomarkers), Ovia Health (women's lifecycle), consumer genetics. All showing strong growth. Expects to break out revenue once critical mass reached. Margins comparable to overall business.
Calendar 2025 Q3
Could you speak a little bit to your efforts around the consumer-driven testing, the contribution you're seeing now from that?
Show response
Adam confirmed very significant growth rate in consumer testing but hasn't reached critical mass for separate reporting. Added tests for lead, ApoB, healthy aging. Ovia app expanding women's health engagement across pregnancy, postpartum, menopause.
Calendar 2025 Q2
What's embedded in your guidance as we head into the second quarter? Is there any normalization in trend or just a continuation of the same?
Show response
Adam confirmed guide assumes 3% volume/1% mix organic split continuing in H2, supported by aging population, disease prevalence and specialty diagnostics. Expects continued market share gains from hospital deals. Julia added ~1/3 of $0.23 EPS raise from operational strength, rest from FX.
Calendar 2025 Q1
on PAMA and versus PAMA reform, what are your latest thoughts in terms of timing and magnitude?
Show response
Adam quantified PAMA at ~$100M annual impact, assumed in base case for 2026. Three-year guidance already includes PAMA. Working with ACLA on better legislation.
Could you break down a little bit in terms of your expectations on underlying organic growth across the Diagnostics business for the balance of the year?
Show response
Adam confirmed ~50/50 organic/inorganic split holds. Julia detailed organic revenue would have been 3.5% ex-weather/days, in line with historical trends.
Calendar 2024 Q4
Could you characterize, I guess, the backdrop right now across Biopharma, what are your expectations in terms of the underlying market into 2025?
Show response
Adam confirmed strong RFP flow, consistent win rate, and cancellations approaching normal. 85% of Central Labs forecast covered by backlog. NHP supply sufficient.
what about PAMA [indiscernible] and just the broader regulatory environment where we stand today with the new administration?
Show response
Adam assumes PAMA in 2026, plan works with or without it. Trade group working on better legislative path forward.
CAHCardinal Health8 questions · 8 reporting periods · 0 of 8 challenging
Calendar 2026 Q2
can you talk about what happened in the quarter
Show response
CFO attributed Pharma strength to broad demand across product categories, higher-margin specialty growth, and above-target generics, and said the momentum carries into FY2027 guidance excluding outsized demand, with 2-3pp benefit from already-completed M&A.
Calendar 2026 Q1
how do we think about to sustain momentum into 2027? What would make you deviate from the long-term growth algo
Show response
CFO emphasized resilience and positive demand trends but deferred specifics to Q4 earnings call. Did not directly address what could cause deviation.
Calendar 2025 Q4
can you unpack or break down some of the components of the profit performance in Pharma Solutions? And can you break down what's organic versus inorganic?
Show response
Jason cited strong demand across all categories, specialty trending above historical levels, MSO contributions consistent with expectations. Solaris contributed 2 months in Q2. Jason confirmed M&A adds ~8% of full-year pharma profit growth. Raised demand assumptions for H2 but not calling outsized demand. Solaris distribution not included in guidance.
Calendar 2025 Q3
has anything surprised you like on an intra-quarter basis that really drove the upside maybe relative to your internal expectations in the quarter? And then maybe you could unpack a little bit of t...
Show response
Jason cited broad-based utilization strength, demographic tailwinds, and innovation pipeline. Aaron detailed specialty trending above historical levels, strong generics volume, MSOs adding 8pp growth. Solaris is 3pp of the 8pp M&A contribution. H1 stronger than H2 due to $7B customer wins.
Calendar 2025 Q2
what are you seeing in terms of utilization trends across the segment? And then on the tariff front, I think you said no change to your expectations there. But just speak to how maybe some of the m...
Show response
Jason confirmed utilization consistent, targeting market growth plus Cardinal Brand penetration gains. Tariff gross exposure ~$450M, $250-300M mitigated operationally, $50-75M in guidance, remainder via pricing as last resort. Targeting run-rate parity by end of FY26. Aaron added Q4 $70M profit was highest quarter; FY26 cadence roughly 1/3 H1, 2/3 H2.
Calendar 2025 Q1
how we should be thinking about that in terms of the progression of pharma growth and the quarterly cadence of this onboarding
Show response
Jason reaffirmed $10B new customer revenue with biggest impact split between Q3 and Q4. Onboarding started in Q2, now at full rollout.
Calendar 2024 Q4
could you talk a little bit, about what you're seeing across specialty right now, just the key drivers
Show response
Jason cited mid-teens specialty growth over recent years, this quarter slightly stronger. Two distinct platforms: Oncology (ION/Navista) and Multi-specialty (GI Alliance).
Calendar 2024 Q3
how do we think about the quarterly progression in medical at this point for the balance of the year
Show response
Aaron detailed health/welfare cost impact (~$45M enterprise), expects sequential quarterly improvement. Jason noted stable medical utilization, cautiously optimistic.
CORCencora8 questions · 8 reporting periods · 0 of 8 challenging
Calendar 2026 Q2
do you anticipate that -- in that context, you can still invest more and lean more into the MSO businesses
Show response
Bob said Cencora intends to keep investing in MSOs via accretive tuck-ins in oncology and retina (the only two specialties it views as pharmaceutical-centric today). Eva described a disciplined guidance process and a capital-deployment strategy of internal investment, strategic M&A, opportunistic buybacks, and a growing dividend.
Calendar 2026 Q1
Do you still see the longer-term opportunities across the MSO assets that are out there
Show response
Jim outlined balanced capital deployment: CapEx investment, strategic M&A, $1B share repurchases through calendar year-end, growing dividend. Paid down $500M of term loans with $1.3B target for fiscal year. See good bolt-on MSO opportunities and recently announced iSouth acquisition.
Calendar 2025 Q4
Can you describe that a little bit more? Is there a specific geography that this was attributable to in terms of in the quarter
Show response
Jim explained timing difference: developing market country manufacturer price adjustment shifted from start to end of Q1. Full-year guidance of 5-8% international OI growth maintained. Global specialty logistics showed volume and operating income growth.
Calendar 2025 Q3
Can you talk a little bit about the overlap with your core business across some of those other businesses that are now in the other segment
Show response
Jim said MWI doesn't provide competitive advantage to the rest of Cencora. Bob explained businesses kept follow human health specialty growth logic: Alliance for European 3PL, World Courier for cell and gene therapy, NMR for Canadian hub/spoke services.
Calendar 2025 Q2
how are you thinking about commitments to the international business, the different components of that business? I'll throw in animal health as well
Show response
Bob confirmed rigorous portfolio discipline to ensure strategic alignment. Would prioritize investment in differentiated growth areas and deprioritize less aligned ones. Did not specifically address international or animal health commitment.
Calendar 2025 Q1
will the RCA deal help to explain your future focus from an M&A standpoint as we think about your learning so far there
Show response
Jim noted OneOncology put/call structure will drive capital deployment over next few years. On GLP-1s: no change in economics, clearly profitable but minimally profitable, remains a revenue driver.
Calendar 2024 Q4
any key therapeutic categories to call out there; and if I can ask a two-parter here, I'm switching species but I'm just curious what you're seeing in animal health
Show response
Jim identified oncology (especially Part B) and ophthalmology/retina as key specialty drivers. Animal health had 7% top line growth with good results in both companion and production markets.
Calendar 2024 Q3
Could you speak a little bit to World Courier? Just give an update on fundamental demand trends across that business
Show response
Bennett noted World Courier market has some softness from clinical trial development but remains growing. Bob added Walgreens is a critically important strategic partner.
CICigna7 questions · 7 reporting periods · 0 of 7 challenging
Calendar 2026 Q2
does that mean that you hit the low end of the 10% to 14% EPS growth in 2027?
Show response
Erin pressed on 2027 PBS growth and the low end of the algorithm; Brian reaffirmed the 10-14% EPS algorithm but deferred formal 2027 segment guidance to the Q4 call. Partial.
Calendar 2026 Q1
how central is specialty to the strategy? How do we think about this in the context of your capital deployment priorities
Show response
Brian confirmed all three growth platforms continue receiving investment without trade-offs. Capital deployment framework remains balanced under new CEO with focus on bolt-on M&A and organic reinvestment.
Calendar 2025 Q4
can you talk about the specialty business? You mentioned some of the strong organic growth there. Can you unpack a little bit some of the key drivers
Show response
Brian highlighted inflammatory, asthma, and allergy as strongest growth TRCs. Specialty now 35% of company, long-term income growth target 8-12%. Humira biosimilar penetration reached vast majority of eligible scripts. $100B of specialty spend subject to biosimilar competition by 2030.
Calendar 2025 Q3
I think you mentioned that roughly in the range of 4% PBM margin would be durable or sustainable even with some of the potential permutations of outcomes from a PBM reform perspective
Show response
Brian confirmed 4% PBM margin benchmark remains reasonable long-term. Earnings contributions from rebate-free model expected comparable to existing solutions at similar client level, though portfolio-level margin may vary with client mix.
Calendar 2025 Q2
Could you give us an update on some of the changes that you're seeing in the retail reimbursement model and landscape with more of the cost-plus models
Show response
Brian said limited client appetite for cost-plus as clients view it as paying more for same value. David reframed broader trend as evolution toward fee-based and performance-based models with enhanced transparency, not pure cost-plus.
Calendar 2025 Q1
Could you describe a little bit more about inReach as well as the InGuide pharmacy role and what these initiatives entail and the economics for Cigna
Show response
Brian explained inReachRx as curated pharmacy network with enhanced clinical support; InGuide as specialized GLP-1 home delivery pharmacy. Economics embedded in EverNorth outlook.
Calendar 2024 Q4
how are you thinking about, I guess capital deployment from an acquisition standpoint, and just any sort of change in your thought process around the regulatory environment
Show response
David confirmed bolt-on M&A strategy unchanged, deployed over $8.5B in 2024, cash flow outlook of 10%+ cash yield for 2025. Specialty and care services highlighted as key growth opportunity.
Show 8 more companies
DGXQuest Diagnostics7 questions · 7 reporting periods · 0 of 7 challenging
Calendar 2026 Q2
I'm just curious what you're seeing across that channel right now, how those relationships are progressing?
Show response
Davis addressed hospital channel directly, breaking out reference vs Co-Lab growth and dismissing bad-debt concerns.
Calendar 2026 Q1
can you speak to the overall margin profile outside of the Quest Direct business?
Show response
Sam confirmed all consumer partnerships at or above enterprise average margin due to cash pay, no denials. Jim detailed AI: 60-70% of efforts inside labs (digitizing microscopy, automating cytology/microbiology/hematology), call center AI, and Quest AI Companion on MyQuest with 350K engagements.
Calendar 2025 Q4
Can you speak to some of the sustainability of growth across this segment, the margin profile?
Show response
Jim detailed wearable partnerships linking biometrics to biomarkers. Subscription renewal rates positive. Sam confirmed questhealth.com grew ~35% FY2025, partnerships above corporate average margin (all cash pay, no denials). Greater than 20% CAGR target maintained.
Calendar 2025 Q3
how would you break the 2 of those out if we do get some sort of more favorable negotiation on the exchange subsidies?
Show response
Sam broke down 60bps: 40-45bps from exchanges, remainder from Medicaid ramping to 2034. Jim explained Epic as 5-7 year transformation: Beaker LIS, MyChart for patients, Care Everywhere connectivity.
Calendar 2025 Q2
how are we trending now into kind of the third quarter? I guess, how would you characterize utilization throughout the quarter as well?
Show response
Jim cited expanded access (Elevance/Sentara, 1M new lives), advanced diagnostics growth, and weather rebound. Q3 start consistent with recent trends.
Calendar 2025 Q1
what are those in terms of what you're making there and what's incremental relative to what you were thinking previously
Show response
Jim said FDA spending will be between $0 and $10M as companion diagnostics and global business still need regulatory infrastructure. Sam confirmed 3-4% wage inflation, turnover improving to mid-high teens.
Calendar 2024 Q4
is it accelerating in terms of the market, underlying market share gains that you're seeing as well? And then also just lastly
Show response
Jim said PAMA reform is ACLA's top priority with new committee chairs engaged. On market share, independent labs making progress as hospitals deprioritize outreach operations.
ELVElevance Health7 questions · 7 reporting periods · 0 of 7 challenging
Calendar 2026 Q2
what you're seeing across Medicare Advantage in terms of just underlying utilization trends.
Show response
Aimee said 2027 bids reflect prudent trend and MA is on track for at least 2% margin, but deferred Stars specifics as too early for PY2028 while citing CAHPS and AI investments.
Calendar 2026 Q1
can you talk about some of the proof points today or progress on that front, quantify any of those efficiency gains
Show response
Gail provided extensive AI proof points: $1B+ investment, 22M members on virtual assistant, 70% reduction in prior auth denials, 60,000+ associates with access, and Sydney matching tool with 20% member engagement.
Calendar 2025 Q4
can you remind us of just your response? I think we know that to some extent, but just ability to mitigate this on top of the cuts that you're making this year as well
Show response
Gail provided comprehensive response: flat rate notice doesn't keep pace with cost and utilization trends, creates pressure on benefit stability for seniors. Will continue disciplined approach and advocate with CMS for appropriate funding. Supported integrity of risk adjustment but changes must be accurate, predictable, and trusted.
Calendar 2025 Q3
Anything to call out on the commercial cost trend? I mean I think you mentioned just broader cost is kind of in line with expectations. But any areas such as behavioral to call out
Show response
Mark noted ACA developed somewhat favorably to prudent expectations despite risk pool deterioration, with pressure in inpatient, behavioral health, pharmacy, and ER. Commercial group trends elevated but in line with some outpatient utilization and higher-cost surgery pockets being monitored.
Calendar 2025 Q2
what are you doing maybe differently in terms of cost structure initiatives throughout the balance of the year and into next year
Show response
Gail detailed multi-pronged approach: AI/technology for process automation, early pattern detection for billing abnormalities, legal action against IDR abuse, and Carelon-led specialty cost management.
Calendar 2025 Q1
Has anything changed on that front? You also have respiratory that you just called out, per the seasonality. I guess where does that leave us for MLR in the second quarter
Show response
Mark identified three factors affecting seasonality: favorable workday calendar pulling earnings forward, Part D design shifts, and membership mix shift toward lower Medicaid/higher ACA.
Calendar 2024 Q4
I wanted to hear your thoughts on the advanced rate notice and where it can go from here in terms of incorporating a catch-up period in the final rate notice
Show response
Felicia welcomed the advance rate notice direction but noted it remains insufficient given cost trends. Gail framed Medicaid regulatory environment as opportunity for public-private partnership.
MCKMcKesson Corporation7 questions · 7 reporting periods · 0 of 7 challenging
Calendar 2026 Q2
is there anything to call out or we should be aware of from a quarterly cadence perspective
Show response
Kenny walked through segment seasonality, the Apollo NCI modeling, the Norway divestiture phasing, and a $51 million US oncology gain lapping in Q2.
Calendar 2026 Q1
What's embedded in guidance in terms of just underlying utilization trends?
Show response
Britt confirmed stable utilization growth over last 2-3 years with specialty pharmaceuticals as the strongest growth category. Health systems specialty positioning remains a key value driver.
Calendar 2025 Q4
can you speak a little bit more about how the transactions are progressing
Show response
Britt maintained year-one accretion guidance for both acquisitions with volumes stable and growing. Prism slightly ahead of acquisition case. Pleased with integration work and volume trends across both platforms.
Calendar 2025 Q3
those gains in terms of rationalization across U.S. oncology. It sounds like that's purely one-off, but any reason we should anticipate those being more frequent
Show response
Britt confirmed O&M gains are nonrecurring. Expressed strong satisfaction with PRISM integration progress, citing Spokane Eye Clinic addition as evidence of platform momentum.
Calendar 2025 Q2
any changes to how you're thinking about that, the impact across kind of U.S. Oncology as well as other businesses
Show response
Brian stated no change in thinking, noting letters just came out July 31 with many facts still needed. Actively engaged with legislature and administration advocating for community-based care.
Calendar 2024 Q4
how do you think about the opportunity across general ophthalmology versus the retina business
Show response
Brian detailed the coordinated care model spanning retina, general ophthalmology, and surgery centers, drawing parallels to oncology platform build. Britt noted current oncology platform at $35 billion revenue.
Calendar 2024 Q3
Can you speak to a little bit more about the nature of this lower utilization?
Show response
Britt tied softness to post-COVID normalization and confirmed ~$100M of H2 savings weighted to Q4.
UNHUnitedHealth Group Incorporated7 questions · 6 reporting periods · 0 of 7 challenging
Calendar 2026 Q3
how should we think about Optum Health margins, where they land in 2027 relative to that 6%-8%?
Show response
Krista Nelson said 2027 will show a strong pace toward the 6%-8% range by 2028, while Steve Hemsley said precision on 2027 must wait for the year-end update.
Calendar 2026 Q2
can some of your AI initiatives actually accelerate or drive upside to the long-term margin targets
Show response
Extensive multi-executive answer with concrete use cases and adoption rates, but no quantified linkage to the long-term margin targets the question asked about.
Calendar 2026 Q1
What should we, though, expect in terms of these savings accelerating in 2027, '28?
Show response
Hemsley said it would be premature to offer guidance on compounding AI impact but affirmed investments are strategically important for competitiveness and will have long-term positive impact mostly for consumers and productivity. Deploying across large core processes and enterprise functions.
I just wanted to be clear what was embedded in guidance from a share repurchase standpoint
Show response
Wayne confirmed original guidance was approximately $2.5B back-half loaded. Accelerated timing due to intrinsic value discount and confidence in results. No changes to total guidance amount, just moved quicker.
Calendar 2025 Q4
has there been any surprises that have come out of some of the initiatives there, especially at OptumCare?
Show response
Nelson said no surprises and actually feels better about 2026 position after Q4 evaluation. Confirmed 6-8% long-term margin target intact. Cited Houston example with 750,000 patients and total cost of care 30% better than competitors. 30% of mature VBC cohorts already at or above target. Emphasized pressure in marketplace makes value-based care more compelling.
Calendar 2025 Q3
Is there anything you can quantify or break down for us in terms of those steps to turn around Optum Health?
Show response
Hemsley acknowledged cannot provide precise quantification as elements blend together. Nelson said progress likely more back-half weighted but progress throughout. Fee-for-service improvements may show faster results while VBC portfolio actions also progressing. Eastern region already showing early results with volume and capture improvements.
Calendar 2025 Q1
what is your latest thinking in terms of just PBM reform?
Show response
Conway cited three major PBM initiatives: 100% rebate pass-through, 25% PA removal, and cost-based pharmacy reimbursement. Raised significant concern about Arkansas PBM legislation signed by governor threatening patient access to integrated behavioral health, specialty medicine, and home infusion. Witty noted encouragement from presidential EO broadening review to full pharmacy value chain.
ALGNAlign Technology6 questions · 6 reporting periods · 0 of 6 challenging
Calendar 2026 Q2
when do you think it will really move the needle from a conversion perspective?
Show response
Morici described good traction and the mechanics of financing but offered no conversion metrics; also confirmed UK VAT is a pass-through.
Calendar 2026 Q1
what you're seeing in terms of growth across brackets and wires versus clear aligners in the market, just more broadly?
Show response
Joe cautioned on third-party data quality. No major change in ortho wires-vs-aligners except preteen where IPE/MAOB/First performing substantially better vs traditional appliances. John said NOAA gross margin is 'excellent' and 'accretive', faster adoption would be upside.
Calendar 2025 Q4
how is broader clear aligner growth across the industry, particularly in the North American market? Comparing to brackets and wires?
Show response
Joe said no material change in wires-and-brackets competitive dynamics between Q4 and rest of year. Younger patient growth is not a wires-and-brackets competition (different devices). Conversion rates in ortho haven't changed dramatically.
Calendar 2025 Q2
Were there any of your own initiatives like promotional activity that didn't really just play out to plan
Show response
Joe and John confirmed no change in promotional strategy; the issue was consumer conversion failure despite strong interest metrics and search volume.
Calendar 2025 Q1
any metrics that you have on the actual conversion rates of Invisalign First and Palate Expander and how you're seeing that translate into growth
Show response
Joe cautioned against calling it critical mass but confirmed good uptake of kids portfolio globally. Noted penetration rate is improving but needs to be tracked quarter-to-quarter.
Calendar 2024 Q4
Just to clarify, so there's no buffer kind of embedded in your guidance as it stands today from a tariff perspective?
Show response
John confirmed no tariff buffer in 22.5% margin guidance. Joe described China market as stable with nothing different from prior trajectory.
HUMHumana5 questions · 5 reporting periods · 0 of 5 challenging
Calendar 2026 Q1
can you remind us on the progress on addressing some of the operating costs?
Show response
Celeste detailed tactical measures: early retirement program completing Q2, internal policy optimization, productivity improvements, vendor consolidation and volume discounts. Strategic: expanding outsourcing in corporate functions (finance, HR) reaching industry benchmarks. Longer-term: relationship consolidation, process standardization, technology automation, operating model centralization.
Calendar 2025 Q4
is there anything specifically on the rate notice that you would have outsized exposure to relative to the industry from a coding perspective
Show response
James said rate notice policy changes do not have V28-level variance; industry should be impacted within narrow band around mean. Celeste said most redomestication work done; still has opportunity in reinsurance for 2027. Very happy with capital optimization progress.
Calendar 2025 Q2
I was wondering if you could talk a little bit more about the Specialty Pharmacy strength and what was kind of driving that
Show response
Celeste described DTC partnerships and winning access to limited distribution drugs as key drivers. Broader specialty industry outperformance plus HUM-specific partnership wins.
Calendar 2025 Q1
how are you thinking now in terms of visibility into that state rate mismatch and how that's progressing now
Show response
George reported ~100K Medicaid growth YTD. Illinois FIDE/LTSS win opens 450K duals. 76% rate visibility. James noted broader state portfolio improves forecasting.
Calendar 2024 Q4
in light of that CMS push for further integration, across Medicare and Medicaid and to service that decent population by 2030
Show response
James described five-year Medicaid plan progressing on trajectory. Noted integration applies only to states that moved forward with HIDE/HIDE SNPs (nearly half). Celeste outlined four investment priorities: membership, Stars, Medicaid growth, and CenterWell.
CVSCVS Health4 questions · 4 reporting periods · 0 of 4 challenging
Calendar 2026 Q2
Can you speak to the timing and magnitude of the technology investments, how we should think about the cadence
Show response
Management detailed AI deployment across claims, colleague and provider workflows, citing over $1 billion of OpEx savings against a $20-plus billion decade-long technology commitment.
Calendar 2025 Q4
can you break down a little bit more what some of those incremental investments are in 2026
Show response
Newman described AI driving savings and growth across enterprise. Shah highlighted open engagement platform progress with potential partnership announcements expected in coming quarters.
Calendar 2025 Q2
I'm curious to your thoughts on the Part D space and how that's playing out kind of relative to plan
Show response
Nelson explained deliberate derisking via reduced plan offerings and design changes. Still digesting new CMS guidance received earlier in the week.
Calendar 2024 Q4
How should we think about the quarterly progression for MLR? You gave us some of the detail on your overall assumptions
Show response
Cowhey provided specific cadence guidance: MBRs lowest in Q1, highest in Q4 with up to eight points of swing due to IRA Part D premium changes.
CNCCentene Corporation2 questions · 2 reporting periods · 0 of 2 challenging
Calendar 2026 Q1
what is your guidance right now
Show response
Drew confirmed same EPS arc as originally guided: step down Q1 to Q2 (still profitable), Q3 around breakeven, Q4 at loss. Medicaid Q2/Q3 HBRs higher than average, Q1/Q4 lower. Commercial/Marketplace steady HBR uptick through year from deductible seasonality. Medicare HBR slope steeper than historical due to PDP being larger proportion of segment. SG&A heaviest in Q4 for open enrollment.
Calendar 2025 Q3
how do you just think about some of the longer-term dynamics across the exchange business, the longer-term margin targets and growth profile
Show response
Sarah reaffirmed long-term marketplace commitment and margin philosophy unchanged. Highlighted ICHRA momentum with administration interest as legacy of Trump first-term legislation, and opportunity to drive individual insurance portability.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| IDXX Idexx Laboratories | 14 | 7%1 of 14 questions |
| ZTS Zoetis | 11 | 27%3 of 11 questions |
| LH LabCorp | 10 | 0%none of 10 questions |
| CAH Cardinal Health | 8 | 0%none of 8 questions |
| COR Cencora | 8 | 0%none of 8 questions |
| CI Cigna | 7 | 0%none of 7 questions |
| DGX Quest Diagnostics | 7 | 0%none of 7 questions |
| ELV Elevance Health | 7 | 0%none of 7 questions |
| MCK McKesson Corporation | 7 | 0%none of 7 questions |
| UNH UnitedHealth Group Incorporated | 7 | 0%none of 7 questions |
- IDXXIdexx Laboratories · 14 questions7%1 of 14 questions
- ZTSZoetis · 11 questions27%3 of 11 questions
- LHLabCorp · 10 questions0%none of 10 questions
- CAHCardinal Health · 8 questions0%none of 8 questions
- CORCencora · 8 questions0%none of 8 questions
- CICigna · 7 questions0%none of 7 questions
- DGXQuest Diagnostics · 7 questions0%none of 7 questions
- ELVElevance Health · 7 questions0%none of 7 questions
- MCKMcKesson Corporation · 7 questions0%none of 7 questions
- UNHUnitedHealth Group Incorporated · 7 questions0%none of 7 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q3 | 3 | 0%none of 3 questions | 3 |
| 2024 Q4 | 15 | 0%none of 15 questions | 12 |
| 2025 Q1 | 14 | 0%none of 14 questions | 11 |
| 2025 Q2 | 14 | 0%none of 14 questions | 12 |
| 2025 Q3 | 12 | 8%1 of 12 questions | 11 |
| 2025 Q4 | 15 | 0%none of 15 questions | 13 |
| 2026 Q1 | 16 | 13%2 of 16 questions | 13 |
| 2026 Q2 | 13 | 8%1 of 13 questions | 12 |
| 2026 Q3 | 1 | 0%none of 1 question | 1 |
- 2024 Q33 questions · challenge rate 0% (none of 3 questions) · 3 companies
- 2024 Q415 questions · challenge rate 0% (none of 15 questions) · 12 companies
- 2025 Q114 questions · challenge rate 0% (none of 14 questions) · 11 companies
- 2025 Q214 questions · challenge rate 0% (none of 14 questions) · 12 companies
- 2025 Q312 questions · challenge rate 8% (1 of 12 questions) · 11 companies
- 2025 Q415 questions · challenge rate 0% (none of 15 questions) · 13 companies
- 2026 Q116 questions · challenge rate 13% (2 of 16 questions) · 13 companies
- 2026 Q213 questions · challenge rate 8% (1 of 13 questions) · 12 companies
- 2026 Q31 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Demand28
- Competitive Dynamics24
- Revenue Growth20
- Regulation Policy20
- Guidance Reliability16
- Margin16
- Product Launch16
- M&A13
- Innovation & R&D10
- Cost Pressure8
Show all 20 topics
- Cloud & AI7
- Capital Allocation6
- Pricing6
- Capex Investment4
- Subscriber Growth3
- Trade Tariffs3
- Geographic Expansion2
- Inventory1
- Labor Market1
- Supply Chain1